Table 2.

Adherence to controller and nebulized SAMAs and SABAs, by study group.

	Refilled ≥ 3 prescriptions of canisters of relievers annually	Refilled < 3 prescriptions of canisters of relievers annually	P value
Annual average PDC of MARTa	0.27 ± 0.36 (0.01, 0.54)	0.15 ± 0.26 (0.03, 0.17)	0.052
Max annual average PDC of controllers (excluding MART)b	0.38 ± 0.34 (0.34, 0.58)	0.24 ± 0.26 (0.13, 0.36)	< 0.001
Annual average number of packages of nebulized SAMAs and SABAsc	1.80 ± 8.34 (0.17, 0.75)	0.67 ± 2.19 (0.00, 0.50)	0.068

Values are mean ± SD (median, IQR).

^aMART, maintenance and reliever therapy.

^bThese controllers include inhaled corticosteroids (ICS) inhalers, leukotriene receptor antagonists (LTRA), ICS + long-acting β2 -agonist (LABA) combinations inhalers, and Theophylline, and exclude controller therapy administered by nebulizers.

^cNebulized short acting beta₂ agonist (SABA) and short-acting muscarinic antagonists (SAMA).